Vimian Group AB (ST:VIMIAN) — Market Cap & Net Worth
Market Cap & Net Worth: Vimian Group AB (VIMIAN)
Vimian Group AB (ST:VIMIAN) has a market capitalization of $1.70 Billion (Skr15.83 Billion) as of May 2, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #6856 globally and #93 in its home market, demonstrating a 0.84% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vimian Group AB's stock price Skr30.10 by its total outstanding shares 525964772 (525.96 Million). Analyse Vimian Group AB cash conversion from operations to see how efficiently the company converts income to cash.
Vimian Group AB Market Cap History: 2021 to 2026
Vimian Group AB's market capitalization history from 2021 to 2026. Data shows change from $4.35 Billion to $1.70 Billion (-17.84% CAGR).
Index Memberships
Vimian Group AB is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
First North Sweden PI
FNSESEKPI
|
$14.99 Billion | 11.37% | #1 of 281 |
Weight: Vimian Group AB's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Vimian Group AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vimian Group AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.04x
Vimian Group AB's market cap is 4.04 times its annual revenue
Latest Price to Earnings (P/E) Ratio
54.87x
Vimian Group AB's market cap is 54.87 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $4.35 Billion | $173.35 Million | $6.59 Million | 25.09x | 660.33x |
| 2022 | $1.49 Billion | $281.31 Million | -$7.20 Million | 5.30x | N/A |
| 2023 | $1.62 Billion | $331.73 Million | $9.84 Million | 4.89x | 164.87x |
| 2024 | $2.25 Billion | $374.80 Million | $18.50 Million | 6.01x | 121.77x |
| 2025 | $1.72 Billion | $425.00 Million | $31.30 Million | 4.04x | 54.87x |
Competitor Companies of VIMIAN by Market Capitalization
Companies near Vimian Group AB in the global market cap rankings as of May 2, 2026.
Key companies related to Vimian Group AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #126 globally with a market cap of $176.29 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #189 globally with a market cap of $123.72 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #578 globally with a market cap of $45.31 Billion USD.
- LONZA GROUP UNSP.ADR 1/10 (F:LO3A): Ranked #643 globally with a market cap of $41.04 Billion USD ( €35.10 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #126 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.29 Billion | $469.21 |
| #189 | Danaher Corporation | NYSE:DHR | $123.72 Billion | $175.15 |
| #578 | IDEXX Laboratories Inc | NASDAQ:IDXX | $45.31 Billion | $567.46 |
| #643 | LONZA GROUP UNSP.ADR 1/10 | F:LO3A | $41.04 Billion | €54.50 |
Vimian Group AB Historical Marketcap From 2021 to 2026
Between 2021 and today, Vimian Group AB's market cap moved from $4.35 Billion to $ 1.70 Billion, with a yearly change of -17.84%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr1.70 Billion | -0.79% |
| 2025 | Skr1.72 Billion | -23.77% |
| 2024 | Skr2.25 Billion | +38.86% |
| 2023 | Skr1.62 Billion | +8.74% |
| 2022 | Skr1.49 Billion | -65.70% |
| 2021 | Skr4.35 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Vimian Group AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.70 Billion USD |
| MoneyControl | $1.70 Billion USD |
| MarketWatch | $1.70 Billion USD |
| marketcap.company | $1.70 Billion USD |
| Reuters | $1.70 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Vimian Group AB
Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic… Read more